TGF-β/Smad pathway was viewed as a target for inflammatory bowel diseases (IBD) treatment for its roles in the suppression of DCs activation and CD8+ T cells function, and the promotion of tolerogenic T cells (79). Here, CD8A is linked to inflammatory bowel disease.